Aptinyx to Present at the 39th Annual J.P. Morgan Healthcare Conference
December 21 2020 - 7:30AM
Business Wire
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced that the
company will present virtually at the 39th Annual J.P. Morgan
Healthcare Conference. Norbert Riedel, Ph.D., chief executive
officer, is scheduled to present on Thursday, January 14, 2021 at
9:10 a.m. Eastern Time.
A live webcast of the presentation will be available to view on
the “Events and Presentations” page in the “Investors & Media”
section of Aptinyx’s website at https://ir.aptinyx.com and will be
archived on Aptinyx’s website for 30 days following the event.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company
focused on the discovery, development, and commercialization of
proprietary synthetic small molecules for the treatment of brain
and nervous system disorders. Aptinyx has a platform for discovery
of novel compounds that work through a unique mechanism to
modulate—rather than block or over-activate—NMDA receptors and
enhance synaptic plasticity, the foundation of neural cell
communication. The company has three product candidates in clinical
development in central nervous system indications, including
chronic pain, post-traumatic stress disorder, and cognitive
impairment associated with Parkinson’s disease. Aptinyx is also
advancing additional compounds from its proprietary discovery
platform, which continues to generate a rich and diverse pipeline
of small-molecule NMDA receptor modulators with the potential to
treat an array of neurologic disorders. For more information, visit
www.aptinyx.com.
Source: Aptinyx Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201221005162/en/
Investor and Media Contact: Nick Smith Aptinyx Inc.
ir@aptinyx.com or corporate@aptinyx.com 847-871-0377
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Apr 2024 to May 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From May 2023 to May 2024